Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,754,300 | $3,675,600 | $3,028,700 | $3,789,200 |
| % Growth | 2.1% | 21.4% | -20.1% | – |
| Cost of Goods Sold | $521,600 | $530,200 | $464,300 | $565,400 |
| Gross Profit | $3,232,700 | $3,145,400 | $2,564,400 | $3,223,800 |
| % Margin | 86.1% | 85.6% | 84.7% | 85.1% |
| R&D Expenses | $1,558,100 | $1,431,700 | $1,339,700 | $1,425,900 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $657,800 | $634,200 | $633,000 | $792,200 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$10,000 | $0 | $0 | $15,500 |
| Operating Expenses | $2,205,900 | $2,065,900 | $1,972,700 | $2,233,600 |
| Operating Income | $1,026,800 | $1,079,500 | $591,700 | $990,200 |
| % Margin | 27.3% | 29.4% | 19.5% | 26.1% |
| Other Income/Exp. Net | $736,500 | $439,200 | $313,300 | -$32,100 |
| Pre-Tax Income | $1,763,300 | $1,518,700 | $905,000 | $958,100 |
| Tax Expense | $303,300 | $127,100 | $96,300 | $40,400 |
| Net Income | $1,460,000 | $1,391,600 | $808,700 | $917,700 |
| % Margin | 38.9% | 37.9% | 26.7% | 24.2% |
| EPS | 14.09 | 13.24 | 7.58 | 8.53 |
| % Growth | 6.4% | 74.7% | -11.1% | – |
| EPS Diluted | 13.62 | 12.81 | 7.27 | 8.06 |
| Weighted Avg Shares Out | 103,620 | 105,100 | 106,700 | 107,900 |
| Weighted Avg Shares Out Dil | 107,200 | 108,600 | 111,200 | 113,800 |
| Supplemental Information | – | – | – | – |
| Interest Income | $175,100 | $174,800 | $173,500 | $183,100 |
| Interest Expense | $19,300 | $3,600 | $8,700 | $10,500 |
| Depreciation & Amortization | $136,700 | $135,100 | $126,900 | $126,400 |
| EBITDA | $1,919,300 | $1,657,400 | $1,040,600 | $1,095,000 |
| % Margin | 51.1% | 45.1% | 34.4% | 28.9% |